Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 4:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 2,815 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: matched control group Clear all

Conditions: Dermatitis, Atopic
Interventions: AN2728 Topical Ointment, 2%, Matching vehicle control; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 2 Years and older
Enrollment: 763 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Stockbridge, Georgia

Conditions: Diabetic Kidney Disease
Interventions: SEL, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 384 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 71
States / cities: Glendale, Arizona • Tucson, Arizona • Canyon Country, California + 59 more

Conditions: Diabetic Nephropathies
Interventions: Placebo matching BI 685509, BI 685509; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 243 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 17
States / cities: Victorville, California • Waterbury, Connecticut • Hialeah, Florida + 13 more

Conditions: Hepatitis B
Interventions: GSK3228836; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Orlando, Florida • San Antonio, Texas

Conditions: Drug-resistant Epilepsy, Focal-Onset Seizures
Interventions: Padsevonil, Placebo; Drug · Other
Lead sponsor: UCB Biopharma S.P.R.L.; Industry
Eligibility: 18 Years and older
Enrollment: 411 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 27
States / cities: Chandler, Arizona • Little Rock, Arkansas • La Jolla, California + 21 more

Conditions: Apical Periodontitis, Endodontic Disease, Root Canal Infection
Interventions: Nanozyme treatment, Control (Standard treatment); Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Renal Impairment, Renal Disease, Kidney Disease
Interventions: Nitazoxanide; Drug
Lead sponsor: Genfit; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 2
States / cities: Miami Lakes, Florida • Orlando, Florida

Conditions: Asthma
Interventions: Dupilumab, Placebo; Drug · Other
Lead sponsor: Sally E. Wenzel MD; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hypercholesterolemia, Atherosclerotic Cardiovascular Disease
Interventions: bempedoic acid, placebo; Drug
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 779 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 2
States / cities: Clearwater, Florida • Georgetown, Texas

Conditions: Relapsing-Remitting Multiple Sclerosis
Interventions: Glatiramer Acetate, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 25
States / cities: Cullman, Alabama • Fresno, California • La Jolla, California + 17 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: GSK3862995B, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Cypress, California • Las Vegas, Nevada

Conditions: Adverse Childhood Experiences, Endothelial Dysfunction
Interventions: Nicotinamide Riboside, Placebo; Dietary Supplement
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 30 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Iowa City, Iowa • Madison, Wisconsin

Conditions: Prostate Cancer
Interventions: Technology based cognitive behavioral stress management, Technology based health promotion group-based attention matched control condition; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 50 Years and older · Male only
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Prevention of Infection With HIV-1
Interventions: ibalizumab (biologic/MAb) for SC Injection or placebo; Biological
Lead sponsor: TaiMed Biologics Inc.; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 6
States / cities: Birmingham, Alabama • Long Beach, California • San Francisco, California + 3 more

Conditions: Obese Patients With Non-alcoholic Steatohepatitis (NASH)
Interventions: LIK066, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 4
States / cities: Baton Rouge, Louisiana • St Louis, Missouri • Knoxville, Tennessee + 1 more

Conditions: Hepatic Impairment
Interventions: Molnupiravir; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 3
States / cities: Hollywood, Florida • Miami, Florida • Philadelphia, Pennsylvania

Conditions: Speech Sound Disorder
Interventions: Biofeedback-ultrasound, Biofeedback--visual-acoustic, Traditional articulation treatment; Behavioral
Lead sponsor: New York University; Other
Eligibility: 9 Years to 15 Years
Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 2
States / cities: Bloomfield, New Jersey • Syracuse, New York

Conditions: Acute Heart Failure With Reduced Ejection Fraction
Interventions: APD418, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 5
States / cities: Tampa, Florida • Peoria, Illinois • Houston, Texas + 2 more

Conditions: Generalized Anxiety Disorder (GAD), Social Anxiety Disorder (SAD), Separation Anxiety Disorder, Specific Phobia, Obsessive Compulsive Disorder (OCD), Panic Disorder (With or Without Agoraphobia)
Interventions: Relaxation and Mentorship Training (RMT), Stepped Care Targeting Exposure and Parenting for Anxiety (STEP-A); Behavioral
Lead sponsor: Andrew Wiese; Other
Eligibility: 7 Years to 17 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Endometriosis, Endometriosis Related Pain, Endometriosis, Pain
Interventions: Dronabinol Capsules, Placebo; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 64 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Hosuton, Texas • Houston, Texas

Conditions: Diabetes Mellitus, Glucose Metabolism Disorders
Interventions: Diazoxide, Nicotinic acid, Placebo; Drug
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 21 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Pancreatic Cancer
Interventions: dasatinib, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 11
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 8 more

Conditions: Coronary Artery Disease
Interventions: TAXUS Liberté-SR, TAXUS™ Express2, Express2; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 261 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 19
States / cities: Sacramento, California • Newark, Delaware • Orlando, Florida + 16 more

Conditions: Polycystic Ovary Syndrome (PCOS), Female Endocrine Disorder
Interventions: AZD4901 (oral), Placebo to match AZD4901; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida • Springfield, Missouri

Search by objective public record fields.

Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis

Study to Evaluate the Efficacy and Safety of Selonsertib in Participants With Moderate to Advanced Diabetic Kidney Disease

A Study to Test the Effect of Different Doses of BI 685509 on Kidney Function in People With Diabetic Kidney Disease

Phase 1 Study of GSK3228836 Pharmacokinetics in Participants With Hepatic Impairment

Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy

Nanozymes in Endodontics

Nitazoxanide Pharmacokinetic Parameters in Renal Impaired Subjects

Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma

Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk

An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GSK3862995B Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and European Ancestry

ACEs, SIRT1, and Premature Vascular Aging in Humans

Technology Based Psychosocial Intervention for Symptom Management and HRQOL in Men Living With Advanced Prostate Cancer

Safety Study of Ibalizumab Subcutaneous Injection in Healthy Volunteers

Effect of LIK066 on Reduction of Fatty Content in Livers of Obese Patients

A Study to Evaluate Molnupiravir (MK-4482) in Participants With Moderate Hepatic Impairment (MK-4482-016)

Correcting Residual Errors With Spectral, Ultrasound, Traditional Speech Therapy

A Study to Assess the Hemodynamic Effects, Safety, Tolerability, and Pharmacokinetics of Intravenous APD418 in Adult Participants With Heart Failure With Reduced Ejection Fraction

Stepped Care Treatment for Anxiety Resilience

Dronabinol As an Adjunct for Reducing Pain (DARP)-Texas Children's Hospital

Regulation of Endogenous Glucose Production by Central KATP Channels

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer

A Study of the TAXUS Liberté Stent for the Treatment of de Novo Coronary Artery Lesions in Small Vessels

A Study of AZD4901 in Females With Polycystic Ovary Syndrome